Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SXTP

60 Degrees Pharmaceuticals Inc

Sep 15 • 01:51PM ET

1.37

-0.03 -2.14 %

Healthcare • Biotechnology • USA • NASD

Peers: GSK PFE MRK JNJ BMY NVS LLY ABBV SAN AZN

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.31	Insider Own	1.85%	Shs Outstand	4.10M	Perf Week	-1.44%
Market Cap	5.62M	Forward P/E	-	EPS next Y	-2.00	Insider Trans	7.06%	Shs Float	4.03M	Perf Month	4.58%
Enterprise Value	13.29M	PEG	-	EPS next Q	-0.46	Inst Own	6.95%	Short Float	2.86%	Perf Quarter	-38.01%
Income	-8.30M	P/S	5.79	EPS this Y	86.73%	Inst Trans	0.42%	Short Ratio	0.21	Perf Half Y	-27.51%
Sales	0.97M	P/B	-	EPS next Y	26.47%	ROA	-183.50%	Short Interest	0.12M	Perf YTD	-78.76%
Book/sh	-4.85	P/C	2.85	EPS next 5Y	-	ROE	-285.78%	52W High	12.45 -89.00%	Perf Year	-78.92%
Cash/sh	0.48	P/FCF	-	EPS past 3/5Y	24.97% 12.29%	ROIC	-322.47%	52W Low	1.22 12.76%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-52.49% -28.10%	Gross Margin	63.74%	Volatility	4.34% 5.76%	Perf 5Y	-
Dividend TTM	-	EV/Sales	13.70	EPS Y/Y TTM	-456.33%	Oper. Margin	-791.84%	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.80	Sales Y/Y TTM	120.67%	Profit Margin	-852.36%	RSI (14)	45.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.27	EPS Q/Q	94.08%	SMA20	1.03%	Beta	2.74	Target Price	3.00
Payout	-	Debt/Eq	0.06	Sales Q/Q	144.93%	SMA50	-8.24%	Rel Volume	0.04	Prev Close	1.40
Employees	3	LT Debt/Eq	0.06	Earnings	Aug 13	SMA200	-53.39%	Avg Volume	558.40K	Price	1.37
IPO	Jul 12, 2023	Option/Short	No / Yes	EPS/Sales Surpr.	6.45% -6.25%	Trades		Volume	14,000	Change	-2.14%

Sep-03-25 08:02AM	60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-21-25 08:31AM	60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-20-25 07:38AM	60 Degrees to commence Phase II babesiosis trial at Mount Sinai (Clinical Trials Arena)
Aug-19-25 08:54AM	60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis (GlobeNewswire)
Aug-13-25 04:14PM	60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results (GlobeNewswire)
05:30PM	Loading…
Aug-04-25 05:30PM	Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-17-25 08:01AM	60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria (GlobeNewswire) -7.93%
Jul-16-25 04:01PM	60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering (GlobeNewswire) -6.29%
Jul-15-25 09:10AM	60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering (GlobeNewswire) -19.17%
07:01AM	60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion (GlobeNewswire)
Jul-14-25 04:01PM	60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025 (GlobeNewswire) -14.09%
Jun-04-25 08:56AM	60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA (tafenoquine) 8-Count Bottle Format (GlobeNewswire)
08:55AM	60 Degrees announces results from an insurance claims analysis on babesiosis (TipRanks)
Jun-03-25 08:49AM	Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals (GlobeNewswire)
May-15-25 04:31PM	60 Degrees Pharmaceuticals Announces First Quarter 2025 Results (GlobeNewswire) +14.88%
05:10PM	Loading…
May-08-25 05:10PM	Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.75%
Apr-22-25 08:44AM	Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey (GlobeNewswire) -15.51%
Apr-10-25 09:24AM	Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday? (Insider Monkey) +24.00%
08:31AM	Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21 (GlobeNewswire)
Apr-08-25 08:31AM	Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health (GlobeNewswire) +59.59%
Mar-28-25 06:59AM	60 Degrees Pharmaceuticals Announces 2024 Annual Results (GlobeNewswire)
Feb-21-25 09:00AM	60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Feb-20-25 10:36AM	60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split (GlobeNewswire) -10.92%
Feb-11-25 12:59PM	Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF (GlobeNewswire)
Feb-06-25 02:07PM	60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Feb-05-25 09:22AM	60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -14.29%
Feb-03-25 08:30AM	RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis (ACCESSWIRE) -14.65%
Jan-30-25 02:20PM	60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -24.53%
Jan-29-25 08:00AM	60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +37.52%
Jan-28-25 08:01AM	60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis (GlobeNewswire) -11.01%
08:30AM	Loading…
Jan-09-25 08:30AM	60 Degrees Pharmaceuticals enrolls first patient in tafenoquine study (TipRanks)
Jan-08-25 08:02AM	60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis (GlobeNewswire) -22.14%
Dec-24-24 09:05AM	60 Degrees, Tufts Medical Center announces patent license agreement (TipRanks) +13.79%
Dec-23-24 08:57AM	Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention (GlobeNewswire) -7.94%
Dec-11-24 08:56AM	60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital (GlobeNewswire) +13.33%
Dec-02-24 04:05PM	VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire)
Nov-22-24 09:00AM	60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Nov-14-24 02:31PM	60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results (GlobeNewswire)
Oct-03-24 09:02AM	60 Degrees Pharmaceuticals Inc. Announces ARAKODA Promotional Pilot in Advance of Expanded U.S. Launch (GlobeNewswire) -7.83%
Sep-06-24 08:59AM	60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -5.56%
Sep-04-24 08:00AM	60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Aug-28-24 02:48PM	60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -8.33%
Aug-14-24 11:01AM	60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results (GlobeNewswire)
Aug-12-24 09:12AM	60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA NDA in Support of SJ733 Phase IIb Study (GlobeNewswire) +44.69%
Aug-06-24 09:26AM	60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split (GlobeNewswire) -16.67%
Jul-25-24 09:02AM	60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA Supply Chain Upgrade Support (GlobeNewswire) +6.40%
Jul-19-24 08:29AM	60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study (GlobeNewswire) +10.16%
Jul-09-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +5.36%
06:31AM	60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment (GlobeNewswire)
Jun-27-24 07:59AM	First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind (GlobeNewswire)
Jun-11-24 07:59AM	60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis (GlobeNewswire)
Jun-06-24 07:38AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +20.67%
May-30-24 07:59AM	Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind (GlobeNewswire) +5.38%
May-20-24 07:59AM	60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study (GlobeNewswire) +24.06%
May-15-24 09:55PM	SXTP Stock Earnings: 60 Degrees Reported Results for Q1 2024 (InvestorPlace)
01:45PM	60 Degrees Pharmaceuticals Announces First Quarter 2024 Results (GlobeNewswire)
May-08-24 07:59AM	60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases (GlobeNewswire) +8.54%
May-02-24 07:59AM	60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required (GlobeNewswire)
Apr-03-24 07:58AM	60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis (GlobeNewswire)
Mar-14-24 07:59AM	60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024 (GlobeNewswire) -7.30%
Feb-20-24 07:59AM	60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris (GlobeNewswire)
Feb-08-24 07:59AM	60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer (GlobeNewswire)
Jan-31-24 12:00PM	WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering (PR Newswire) -8.75%
11:15AM	60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering (GlobeNewswire)
Jan-30-24 09:45AM	WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering (PR Newswire) -40.58%
09:00AM	60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering (GlobeNewswire)
Jan-22-24 07:59AM	60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting (GlobeNewswire) +19.97%
Jan-16-24 07:59AM	60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Dec-26-23 07:59AM	60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024 (GlobeNewswire) +28.09%
Nov-15-23 07:29AM	60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease (GlobeNewswire) +17.93%
Oct-19-23 08:31AM	60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston (GlobeNewswire) +8.15%
Oct-12-23 04:16PM	60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases (GlobeNewswire) -5.42% +6.73%
Sep-18-23 04:16PM	60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements (GlobeNewswire) -25.48%
Sep-06-23 07:31AM	60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-01-23 09:00AM	Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV (ACCESSWIRE)
Aug-30-23 07:32AM	60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity (GlobeNewswire) +7.04%
Aug-22-23 07:31AM	60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria (GlobeNewswire) -5.92%
Aug-15-23 07:31AM	60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov (GlobeNewswire) +7.23%
Jul-31-23 07:59AM	60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects (GlobeNewswire) +6.16%
Jul-21-23 09:00AM	60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) (ACCESSWIRE) -8.56%
Jul-14-23 01:30PM	WallachBeth Capital Announce Closing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit (PR Newswire) -15.67%
12:39PM	60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering (GlobeNewswire)
Jul-12-23 01:45PM	WallachBeth Capital Announce Pricing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit (PR Newswire)
12:29PM	60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering (GlobeNewswire)

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
XU CHERYL	Director	Jun 03 '25	Buy	2.88	5,000	14,410	15,816	Jun 05 08:53 PM
XU CHERYL	Director	Dec 13 '24	Buy	1.56	6,000	9,375	52,078	Dec 18 08:35 PM
XU CHERYL	Director	Dec 12 '24	Buy	1.82	5,000	9,125	46,078	Dec 18 08:35 PM
XU CHERYL	Director	Dec 16 '24	Buy	1.45	2,000	2,900	54,078	Dec 18 08:35 PM
DOW GEOFFREY S	President and CEO	Dec 09 '24	Buy	1.27	35,823	45,563	94,580	Dec 09 05:07 PM
DOW GEOFFREY S	President and CEO	Dec 06 '24	Buy	1.20	20,579	24,672	58,757	Dec 09 05:07 PM
DOW GEOFFREY S	President and CEO	Dec 05 '24	Buy	1.11	17,549	19,520	38,178	Dec 09 05:07 PM
DOW GEOFFREY S	President and CEO	Nov 21 '24	Buy	0.91	3,500	3,195	20,629	Nov 21 06:14 PM
DOW GEOFFREY S	President and CEO	Nov 19 '24	Buy	0.90	2,500	2,248	16,129	Nov 21 06:14 PM
DOW GEOFFREY S	President and CEO	Nov 20 '24	Buy	0.92	1,000	924	17,129	Nov 21 06:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SXTP

60 Degrees Pharmaceuticals Inc

Upgrade your FINVIZ experience